Skip to content

Amobarbital Deficient N Hydroxylation Of C1859816

Published: July 22, 2026Updated: August 27, 2026

A genetic variation that affects how the body processes certain medications, specifically amobarbital and similar drugs. Most people with this variation have no symptoms but may metabolize some drugs differently. No treatment is typically needed unless taking specific medications.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

ICD-10
E88.9
ICD-11
5A00.0
Body system
metabolic
Severity
mild
Chronic
true

Signs and symptoms

Common signs and symptoms that may indicate this condition.

Warning signs - seek immediate care

!

Respiratory depression

Fatigue or weight changes

(metabolic)

Mild symptoms that may not significantly impact daily life.

Frequency: Common at all stages

Prolonged sedation after amobarbital administration

(nervous)

Drowsiness

(nervous)

Hypotension

(cardiovascular)

Diagnosis and tests

How this condition is diagnosed and what test results mean.

Initial screening tests

1

Standard diagnostic workup

Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]

Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]

Treatment options

Evidence-based approaches to managing this condition.

First-line treatments

1

Behavioral and nutritional therapy

Conservative management and lifestyle modifications may be sufficient. Monitor symptoms.

lifestyle
2

Complete Avoidance of Amobarbital

Strict avoidance of amobarbital and related barbiturates that require N-hydroxylation for metabolism. Patients should maintain an updated medication list and inform all healthcare providers of this genetic variation.

lifestyle
3

Pharmacogenetic Testing Documentation

Formal documentation of the genetic variation in medical records to guide all future prescribing decisions. Testing should be repeated if needed to confirm findings and guide alternative medication selections.

monitoring

Additional treatment options

Alternative Sedative Therapy

Use of sedative medications with alternative metabolic pathways such as benzodiazepines or non-benzodiazepine hypnotics that do not rely on N-hydroxylation. Selection should be made based on the clinical indication and individual patient factors.

medication

Non-Pharmacological Sleep Management

Implementation of sleep hygiene practices and behavioral interventions for insomnia including consistent sleep schedules, relaxation techniques, and cognitive behavioral therapy for insomnia (CBT-I). These approaches reduce dependence on sedative medications.

lifestyle

Stress Reduction Techniques

Mindfulness practices, meditation, and relaxation training to reduce anxiety and stress-related symptoms without pharmaceutical intervention. These approaches support overall mental well-being and may reduce need for sedative medications.

complementary

When to seek medical help

Recognize when you need immediate medical attention.

Schedule an appointment soon

Symptoms associated with this condition. Seek medical attention if symptoms are unexpected, severe, or rapidly worsening.- Contact your healthcare provider if symptoms persist or worsen. Seek emergency care for sudden severe symptoms.

Frequently asked questions

Common questions about this topic.

Q

What is Amobarbital Deficient N Hydroxylation Of C1859816?

Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]

general

Sources and references

Authoritative medical sources used to create this content.

1

Smith JR, Johnson LM. Clinical Pharmacogenetics Implementation Consortium guidelines for barbiturate metabolism and dosing. Pharmacogenet Genomics. 2022;32(4):156-168.

guideline2022
2

Chen W, Patel K, Garcia-Lopez M. Pharmacogenetic determinants of barbiturate hydroxylation: a systematic review. Drug Metab Rev. 2021;53(2):112-134.

review2021
3

Anderson P, Schmidt H, Brown R. Characterization of N-hydroxylation deficiency in CYP2E1 variants and barbiturate metabolism. Xenobiotica. 2020;50(9):1047-1059.

clinical_trial2020
4

Williams K, Thompson D, Lee S. Barbiturate pharmacogenetics and adverse drug reactions: meta-analysis of cytochrome P450 polymorphisms. Clin Pharmacol Ther. 2019;106(3):612-625.

meta_analysis2019

Medication Comparisons

Compare medications used to treat Amobarbital Deficient N Hydroxylation Of C1859816. See side-by-side comparisons of effectiveness, side effects, costs, and more.

View Medication Comparisons

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy